Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina
Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina
Atherosclerotic cardiovascular disease is a leading cause of mortality in our countries. Clinically, symptoms could be chest pain suggesting stable angina. Atherosclerosis is influenced by cardiovascular risk factors which obesity (Body Mass Index>30). Obesity is associated with an increase risk of cardiovascular complications.
Lipoprotein(a) is regarded as an independent risk factor for premature cardiovascular disease. Lp(a) is composed of low-density lipoprotein - like particle bound to glycoprotein molecule: apolipoprotein(a). Plasma levels are determinated to more than 90% by genetic factors (no significant influence of statin, weight, lifestyle factor: diet, exercise). Two study with few patients have found that aspirin lowers serum Lp(a) levels. Elevated Lp(a) is a risk factor for recurrent coronary events in obese patient.
Atherosclerosis is associated with imbalance of coagulation. TFPI (tissue factor pathway inhibitor) is the earliest inhibitor of the blood coagulation process, natural direct inhibitor of tissue factor. In-vitro, TFPI activity is inhibited by high Lp(a) .
The aim of this study is to research reverse association between Lp(a) and TFPI activity in obese patient with chest pain like stable angina suggesting atherosclerotic heart disease and effect of aspirin.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Feurs、法国、42110
- Service de cardiologie - CHG Feurs
-
Firminy、法国、42700
- Service de cardiologie - CHG Firminy
-
Saint-Etienne、法国、42055
- Service de cardiologie - CHU de Saint-Etienne
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Major
- Men
- Obese BMI>30
- No aspirin treatment before inclusion
- Coronary exploration: coronary angiography or tomography coronary angiography
- Chest pain like stable angina
Exclusion Criteria:
- Women
- Severe hepatic insufficiency
- Inflammatory disease
- Neoplasia
- Protein S deficiency
- Aspirin treatment 10 days before inclusion
- Oral anticoagulant treatment at inclusion
- Heparin or low molecular weight heparin treatment at inclusion
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
obese men
obese men with chest pain like angina
|
blood sample at inclusion and 1 month after inclusion
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
correlation between Lp(a) and TFPI activity
大体时间:day 1
|
Establish correlation between Lp(a) rate and TFPI activity in obese patients with chest pain like stable angina
|
day 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Correlation between Lp(a) and TFPI resistance
大体时间:day 1
|
Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment
|
day 1
|
Correlation between lp(a) rate and TFPI activity
大体时间:1 month
|
Establish the correlation, 1 month after initiation of aspirin treatment, between lp(a) rate and TFPI activity
|
1 month
|
thrombin generation
大体时间:day 1
|
describe thrombin generation with calibrated automated thrombinography technique in obese patient with chest pain like angina and hight Lp(a)rate
|
day 1
|
Correlation between Lp(a) and TFPI resistance
大体时间:1 month
|
Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment
|
1 month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.